# Research Questions

## Contents

- [How can biopharma/biotech organizations reconstruct decision logic when FDA requests justification months or years after decisions were made?](q1/)
- [How can AI-assisted regulatory processes preserve human accountability while leveraging AI's efficiency gains?](q2/)
- [How can decision governance frameworks integrate with existing biopharma/biotech project management practices without adding bureaucratic overhead?](q3/)
- [How can schema-validated decision logs reduce FDA deficiency rates and clinical hold risks?](q4/)
- [How can decision cycle time be compressed while maintaining decision quality and regulatory defensibility?](q5/)
- [How will decision governance reshape regulatory interactions, investor due diligence, and board governance in biopharma/biotech development?](q6/)
- [How can organizations measure the ROI of decision governance infrastructure across portfolio-level timelines and outcomes?](q7/)
- [How should implementation roadmaps balance pilot validation, organizational integration, and thought leadership positioning?](q8/)
- [How can AI governance disclosure frameworks satisfy evolving FDA expectations for transparency in algorithmic decision-making?](q9/)
- [How should regulatory frameworks evolve to mandate or incentivize decision documentation as standard practice in biopharma/biotech submissions?](q10/)
